Abbott’s flagship CGM now powers Tandem’s Control-IQ+ system—with more pump integrations and a ketone sensor on the horizon.
Tandem, Beta Bionics, Sequel Med Tech, and Ypsomed are the first to announce integration plans for Abbott’s dual-analyte sensor with more expected.
Tandem Diabetes is already telling patients its smartphone app to control the Mobi insulin pump will arrive by the end of 2025.
After three years with Omnipod, a tubed pump taught me something new about tech—and myself
Tandem’s SteadiSet just received FDA 510(k) clearance—and it could soon bring 7-day wear to more insulin pump users.
The switch from a tubeless to a tubed pump had its challenges.
Control-IQ+ Technology expands access and flexibility for stronger diabetes management
